Open- Label Trial of Sipuleucel-T Administered to Active Surveillance Patients for Newly Diagnosed Prostate Cancer
Completed · Phase 3 · NCT03686683
Conditions: Adenocarcinoma of the Prostate
At a glance
- Research payments reported, 2025
- $4,092
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 532
About the trial
- Sponsor
- Dendreon (with PRA Health Sciences)
- Tested
- sipuleucel-T (biological)
- Dates
- Started 2018-10-18; completion 2023-03-10
- Results posted
- Yes
The ProVent study is a randomized, open-label study designed to assess the efficacy of sipuleucel-T in reducing the progression of lower risk non-metastatic prostate cancer compared to participants followed on active surveillance as standard of care.
From ClinicalTrials.gov, last updated 2024-10-08. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Dendreon Pharmaceuticals LLC reported $4,092 in research payments for this study in 2025 (1 payments).
Products named: Provenge
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Genesis Research LLC $4,092
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.